

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Presidio Partners 2007 GP, L.P.</u> (Last) (First) (Middle) 655 MONTGOMERY STREET, SUITE 6-161, (Street) SAN FRANCISCO CA 94111 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Menlo Therapeutics Inc. [MNLO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/02/2018	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/02/2018		J ⁽¹⁾		152,062	A	\$0	152,062	I	By David J. Collier ⁽²⁾
Common Stock								2,395,068	I	By Presidio Partners 2007, L.P. ⁽³⁾
Common Stock								61,410	I	By Presidio Partners 2007 (Parallel), L.P. ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*

[Presidio Partners 2007 GP, L.P.](#)

(Last) (First) (Middle)
655 MONTGOMERY STREET, SUITE 6-161,

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Presidio Partners 2007 \(Parallel\), L.P.](#)

(Last) (First) (Middle)
C/O PRESIDIO PARTNERS 2007 GP, L.P.
655 MONTGOMERY STREET, SUITE 6-161

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Presidio Partners 2007, L.P.](#)

(Last) (First) (Middle)
C/O PRESIDIO PARTNERS 2007 GP, L.P.
655 MONTGOMERY STREET, SUITE 6-161

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Collier David J](#)

(Last) (First) (Middle)
C/O PRESIDIO PARTNERS 2007 GP, L.P.
655 MONTGOMERY STREET, SUITE 6-161

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Watson James F](#)

(Last) (First) (Middle)
C/O PRESIDIO PARTNERS 2007 GP, L.P.
655 MONTGOMERY STREET, SUITE 6-161

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Sohail Faysal A.

(Last) (First) (Middle)

C/O PRESIDIO PARTNERS 2007 GP, L.P.
655 MONTGOMERY STREET, SUITE 6-161

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

Explanation of Responses:

1. Pro rata distribution from Velocity Pharmaceutical Development, LLC, of which the reporting person is a non-managing member.
2. Securities directly held by David J. Collier, M.D., a general partner of Presidio GP (as defined below), which is the sole general partner of Presidio Partners (as defined below).
3. Securities directly held by Presidio Partners 2007, L.P. ("Presidio Partners"). Presidio Partners 2007 GP, L.P. ("Presidio GP") is the sole general partner of Presidio Partners. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio GP, and may be deemed to have voting control and investment power over the securities held by Presidio Partners, but disclaim beneficial ownership of the securities held by Presidio Partners, except to the extent of their pecuniary interest therein.
4. Securities directly held by Presidio Partners 2007 (Parallel), L.P. ("Presidio Parallel"). Presidio GP is the sole general partner of Presidio Parallel. David Collier, M.D., James Watson and Faysal Sohail are the general partners of Presidio Parallel, and may be deemed to have voting control and investment power over the securities held by Presidio Parallel, but disclaim beneficial ownership of the securities held by Presidio Parallel, except to the extent of their pecuniary interest therein.

Presidio Partners 2007 GP,
L.P. By: Presidio Partners
2007 GP LLC, its General
Partner, /s/ David J. Collier,
Manager 07/26/2018

PRESIDIO PARTNERS 2007
(Parallel), L.P. By: Presidio
Partners 2007 GP, L.P. its
General Partner By: Presidio
Partners 2007 GP LLC, its
General Partner, /s/ David J.
Collier, Manager 07/26/2018

PRESIDIO PARTNERS 2007,
L.P. By: Presidio Partners
2007 GP, L.P. its General
Partner By: Presidio Partners
2007 GP LLC, its General
Partner, /s/ David J. Collier,
Manager 07/26/2018

/s/ David J. Collier 07/26/2018

/s/ James F. Watson 07/26/2018

/s/ Faysal A. Sohail 07/26/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.